{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443877867
| IUPAC_name = ''N''-isopropylisonicotinohydrazide
| image = Iproniazid.svg
| width = 150
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|iproniazid}}
| pregnancy_category =
| legal_status =
| routes_of_administration = 
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 54-92-2
| ATC_prefix = N06
| ATC_suffix = AF05
| PubChem = 3748
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04818
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3617
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = D892HFI3XA
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02579
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 92401
<!--Chemical data-->
| C=9 | H=13 | N=3 | O=1
| molecular_weight = 179.219 g/mol
| smiles = O=C(NNC(C)C)c1ccncc1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NYMGNSNKLVNMIA-UHFFFAOYSA-N
}}

'''Iproniazid''' ('''Marsilid''', '''Rivivol''', '''Euphozid''', '''Iprazid''', '''Ipronid''', '''Ipronin''') is a non-selective, [[irreversible inhibition|irreversible]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] class.<ref name="bookDrug discovery">{{cite book |author1=Robert A. Maxwell |author2=Shohreh B. Eckhardt | title = Drug discovery | publisher = Humana Press | year = 1990 | pages = 143–154 | isbn = 0-89603-180-2 |id={{ISBN|9780896031807}} }}</ref><ref name="pmid2870717">{{cite journal |vauthors=Fagervall I, Ross SB |title=Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors |journal=[[Biochemical Pharmacology (journal)|Biochemical pharmacology]] |volume=35 |issue=8 |pages=1381–7 |date=April 1986 |pmid=2870717 |doi= 10.1016/0006-2952(86)90285-6|url=http://linkinghub.elsevier.com/retrieve/pii/0006-2952(86)90285-6}}</ref> It was discontinued in most of the world in the 1960s, but remained in use in [[France]] until fairly recently.<ref name="pmid10592880">{{cite journal |vauthors=Maille F, Duvoux C, Cherqui D, Radier C, Zafrani ES, Dhumeaux D | title = [Auxiliary hepatic transplantation in iproniazid-induced subfulminant hepatitis. Should iproniazid still be sold in France?] | language = French | journal = Gastroenterol. Clin. Biol. | volume = 23 | issue = 10 | pages = 1083–5 |date=October 1999  | pmid = 10592880 | doi = | url = }}</ref>

Iproniazid was originally developed for the treatment of [[tuberculosis]],<ref name="bookDrug discovery"/> but in 1952, its antidepressant properties were discovered when researchers noted that patients given [[isoniazid]] became inappropriately happy.<ref name="bookDrug discovery"/><ref>{{Cite journal|last=Ramachandraih|first=Chaitra T.|last2=Subramanyam|first2=Narayana|last3=Bar|first3=Kral Jurgen|last4=Baker|first4=Glen|last5=Yeragani|first5=Vikram K.|date=2011|title=Antidepressants: From MAOIs to SSRIs and more|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136031/|journal=Indian Journal of Psychiatry|volume=53|issue=2|pages=180–182|doi=10.4103/0019-5545.82567|issn=0019-5545|pmc=3136031|pmid=21772661}}</ref> Subsequently N-isopropyl addition led to development as an antidepressant and was approved for use in 1958.<ref name="bookDrug discovery"/> It was withdrawn a few years later in 1961 due to a high incidence of [[hepatitis]], and was replaced by less [[hepatotoxic]] drugs such as [[phenelzine]] and [[isocarboxazid]].<ref name="bookDrug discovery"/>

Although iproniazid was one of the first [[antidepressant]]s ever marketed, [[amphetamine]] (marketed as [[Benzedrine]] from 1935, for "mild depression", amid other indications)<ref name="Amph Uses Dex">{{cite journal |vauthors=Heal DJ, Smith SL, Gosden J, Nutt DJ | title = Amphetamine, past and present – a pharmacological and clinical perspective | journal = J. Psychopharmacol. | volume = 27 | issue = 6 | pages = 479–96 |date=June 2013 | pmid = 23539642 | pmc = 3666194 | doi = 10.1177/0269881113482532}}</ref> predates it; and [[frankincense]] has been marketed traditionally for millennia for, among other things, altering mood, although it was not until 2012 that one of the components of its smoke was found to have antidepressant effects in mice.<ref>{{cite journal
| first1=Arieh| last1=Moussaieff 
| first2=Neta| last2=Rimmerman 
| first3=Tatiana| last3=Bregman 
| first4=Alex| last4=Straiker 
| first5=Christian C.| last5=Felder 
| first6=Shai| last6=Shoham 
| first7=Yoel| last7=Kashman 
| first8=Susan M.| last8=Huang 
| first9=Hyosang| last9=Lee 
| first10=Esther| last10=Shohami 
| first11=Ken| last11=Mackie 
| first12=Michael J.| last12=Caterina 
| first13=J. Michael| last13=Walker 
| first14=Ester| last14=Fride 
| first15=Raphael| last15=Mechoulam
| url=http://www.fasebj.org/content/22/8/3024
| title=Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain
| publisher=The FASEB Journal |volume=22 |issue=8 |pages=3024–3034 
| date=August 2008 
| pmid=18492727 |pmc=2493463 |doi=10.1096/fj.07-101865}}</ref>
<ref>{{cite journal 
| doi = 10.1177/0269881112458729 
| title = Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals 
| year = 2012 
| last1 = Moussaieff | first1 = A 
| last2 = Gross | first2 = M 
| last3 = Nesher | first3 = E 
| last4 = Tikhonov | first4 = T 
| last5 = Yadid | first5 = G 
| last6 = Pinhasov | first6 = A 
| journal = J Psychopharmacol. | volume = 26 | issue = 12 
| pmid=23015543}}</ref>
<ref>{{cite journal
| title=Frankincense And Myrrh 
| first=Carmen | last=Drahl 
| journal=Chemical & Engineering News | issn=0009-2347 | volume=86 |issue=51 | page=38 
| date=22 December 2008
| url=http://pubs.acs.org/cen/whatstuff/86/8651sci2.html 
| doi=10.1021/cen-v086n051.p038}}</ref>

== See also ==
* [[Hydrazine (antidepressant)]]
*[[Nialamide]]

== References ==
{{Reflist|2}}

{{Antidepressants}}
{{Monoamine metabolism modulators}}
{{Hydrazines}}

[[Category:Monoamine oxidase inhibitors]]
[[Category:Hepatotoxins]]
[[Category:Hydrazides]]
[[Category:Isonicotinamides]]
[[Category:Withdrawn drugs]]


{{nervous-system-drug-stub}}